Evidence map›Paper›PMID 17508279›Full record

ArticleBreast cancer research and treatment2008

Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.

Mariam A Stoff-Khalili, Angel A Rivera, Ana Nedeljkovic-Kurepa, Arrigo DeBenedetti, Xiao-Lin Li, Yoshinobu Odaka, Jagat Podduturi, Don A Sibley, Gene P Siegal, Alexander Stoff and 4 more

Abstract read
In one paragraph

Article in Breast cancer research and treatment, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Oncolytic virotherapy.Nature biotechnology · 2012
    Review
  9. Article
  10. Article
  11. Article
  12. Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2010
    Article
  13. Current issues and future directions of oncolytic adenoviruses.Molecular therapy : the journal of the American Society of Gene Therapy · 2010
    Review
  14. Article
  15. Article
  16. MicroRNAs and the regulation of vector tropism.Molecular therapy : the journal of the American Society of Gene Therapy · 2009
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mariam A Stoff-KhaliliDivision of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294-2172, USA.
Angel A Rivera
Ana Nedeljkovic-Kurepa
Arrigo DeBenedetti
Xiao-Lin Li
Yoshinobu Odaka
Jagat Podduturi
Don A Sibley
Gene P Siegal
Alexander Stoff
Scott Young
Zheng B Zhu
David T Curiel
J Michael Mathis

Funding

COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
Translational Applications of mda-7/IL-24 in CancerP01CA104177 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GUPTA, PANKAJ · 2005 to 2009
$6.5M
UAB Core Center for Musculoskeletal DisordersP30AR046031 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CAO, XU · 2001 to 2010
$5.6M
REPLICATIVE ADENOVIRUSES WITH ENHANCED INFECTIVITYR01CA083821 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CURIEL, DAVID TERRY · 2000 to 2008
$1.9M
Targeted Gene Therapy for LymphomaR01CA113454 · NCI · AUBURN UNIVERSITY AT AUBURN · PI SMITH, BRUCE F. · 2006 to 2010
$1.3M
Canine model for evaluating CRAD efficacyR01CA093796 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SIEGAL, GENE P · 2002 to 2005
$1.1M
Cancer dual-targeting of an infectivity-enchanced CRAdR41CA114921 · NCI · VECTORLOGICS, INC. · PI MATHIS, J. MICHAEL · 2006 to 2006
$100k
NCI NIH HHS P01 CA 104177NCI NIH HHS P01 CA104177NCI NIH HHS R01 CA 083821NCI NIH HHS R01 CA083821NCI NIH HHS R01 CA093796NCI NIH HHS R01 CA 113454NCI NIH HHS R01 CA113454NCI NIH HHS R01 CA 93796NCI NIH HHS R01 CA 98543NCI NIH HHS R41 CA 114921NCI NIH HHS R41 CA114921NCI NIH HHS U10 CA098543NIAMS NIH HHS AR 46031NIAMS NIH HHS P30 AR046031
6 · The paper itself

Abstract

backgroundIn view of the limited success of available treatment modalities for a wide array of cancer, alternative and complementary therapeutic strategies need to be developed. Virotherapy employing conditionally replicative adenoviruses (CRAds) represents a promising targeted intervention relevant to a wide array of neoplastic diseases. Critical to the realization of an acceptable therapeutic index using virotherapy in clinical trials is the achievement of oncolytic replication in tumor cells, while avoiding non-specific replication in normal tissues. In this report, we exploited cancer-specific control of mRNA translation initiation in order to achieve enhanced replicative specificity of CRAd virotherapy agents. Heretofore, the achievement of replicative specificity of CRAd agents has been accomplished either by viral genome deletions or incorporation of tumor selective promoters. In contrast, control of mRNA translation has not been exploited for the design of tumor specific replicating viruses to date. We show herein, the utility of a novel approach that combines both transcriptional and translational regulation strategies for the key goal of replicative specificity.

methodsWe describe the construction of a CRAd with cancer specific gene transcriptional control using the CXCR4 gene promoter (TSP) and cancer specific mRNA translational control using a 5'-untranslated region (5'-UTR) element from the FGF-2 (Fibroblast Growth Factor-2) mRNA.

resultsBoth in vitro and in vivo studies demonstrated that our CRAd agent retains anti-tumor potency. Importantly, assessment of replicative specificity using stringent tumor and non-tumor tissue slice systems demonstrated significant improvement in tumor selectivity.

conclusionsOur study addresses a conceptually new paradigm: dual targeting of transgene expression to cancer cells using both transcriptional and mRNA translational control. Our novel approach addresses the key issue of replicative specificity and can potentially be generalized to a wide array of tumor types, whereby tumor selective patterns of gene expression and mRNA translational control can be exploited.

Indexed as

Protein BiosynthesisTranscription, Genetic5' Untranslated RegionsAdenoviridaeAdenovirus E1A ProteinsAnimalsBlotting, WesternBreast NeoplasmsE1A-Associated p300 ProteinFemaleFibroblast Growth FactorsGenetic VectorsHumansMiceMice, NudeOncolytic Virotherapy5' Untranslated RegionsAdenovirus E1A ProteinsE1A-Associated p300 ProteinFibroblast Growth FactorsReceptors, CXCR4RNA, Messenger

Identifiers

PMID17508279
PMCPMC2268614

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.